Free Trial

Fresenius Medical Care (ETR:FME) Stock Passes Above 200-Day Moving Average - Time to Sell?

Fresenius Medical Care logo with Medical background

Fresenius Medical Care AG (ETR:FME - Get Free Report) shares passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of €45.75 ($53.20) and traded as high as €47.23 ($54.92). Fresenius Medical Care shares last traded at €47.17 ($54.85), with a volume of 466,778 shares traded.

Fresenius Medical Care Stock Performance

The firm has a market cap of $13.75 billion, a PE ratio of 20.86, a price-to-earnings-growth ratio of 0.42 and a beta of 0.86. The company has a 50 day simple moving average of €44.14 and a 200-day simple moving average of €45.75. The company has a debt-to-equity ratio of 82.24, a current ratio of 1.37 and a quick ratio of 0.80.

Fresenius Medical Care Company Profile

(Get Free Report)

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Fresenius Medical Care Right Now?

Before you consider Fresenius Medical Care, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius Medical Care wasn't on the list.

While Fresenius Medical Care currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.